Table 2.

Association of Met[67]Val substitution (SNP3) in Stage I and II.

Trait	Met[67]Val	Sample 3 Finnish FCHL				Sample 4 Finnish CVR				Stage I+II
		N=715	Z*V/V	Z* M/V	R2†	N=1,371			R2†	P§
							β̂ ‡add(SE)	β̂ ‡dev(SE)
	Val/Val	6.47±0.23				5.61±0.09
TC	Met/Val	5.96±0.11	1.78	−1.68	2.37%	5.56±0.04	0.09(0.05)	0.05(0.06)∥	0.54%	0.0009
(mmol/L)	Met/Met	6.15±0.12				5.43±0.04
	Val/Val	4.22±0.20				3.60±0.08
LDL-C	Met/Val	3.82±0.10	2.07	−1.71	2.34%	3.57±0.04	0.07(0.05)	0.04(0.06)∥	0.32%	0.0072
(mmol/L)	Met/Met	3.99±0.10				3.48±0.03
	Val/Val	1.32±0.07				1.10±0.03
ApoB	Met/Val	1.11±0.03	2.32	−1.32	3.03%	1.12±0.01	0.03(0.05)	0.08(0.07)∥	0.28%	0.0049
(g/L)	Met/Met	1.13±0.03				1.09±0.01

Trait values represent the marginal mean evaluated at the average age and sex ±SEM.

^*Z_V/V, indicates the Z value obtained from the FBAT genotypic model test for the Val/Val genotype and Z_M/V for the Met/Val genotype.

^†R² indicates the proportion of variance explained by the genotypic model.

^‡β̂ _add, indicates the standardized beta coefficients per each copy of the rare allele (additive term) and β̂ _dev for the dominance-deviation term.

^§The p-values represent the results of the combined analysis of stage 1 and 2, as described in Methods.

^∥P > 0.1 for the significance of deviation from an additive model.